Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene test could personalize stroke prevention

NCT ID NCT05763862

Disease control Sponsor: National Neuroscience Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether genetic testing can help doctors pick the right antiplatelet medicine for people who have had a stroke or mini-stroke. About 350 patients will be randomly assigned to either standard care or a genetic test that checks if a common drug, clopidogrel, is likely to work for them. If the test shows the drug may not be effective, patients will receive alternative medications. The goal is to see if this personalized approach reduces the chance of another stroke or heart problem over the next year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
genetic testing for CYP2C19 mutations
What this could lead to
If successful, this could show that tailoring antiplatelet drugs based on genetics reduces the risk of another stroke or heart attack.
What could go wrong
This is a relatively small, early-stage feasibility study, and the benefit of genetic testing over standard care is not yet proven. Bleeding risks from alternative antiplatelet drugs also remain a concern.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 350 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with acute ischemic stroke or transient ischemic attack. * Age 21 years to 100 years. * Can be randomised within 7 days of onset of index event \[Refer to footnote 1\]. * Clopidogrel naive immediately prior to index event \[Refer to footnote 2\]. Footnote 1: Date of index event to be taken as Day 1. This means that randomisation must be done by Day 7. For unknown onset or wake-up stroke where the last seen well and symptoms discovery are on different days, Day 1 is taken to be the date of symptoms discovery. Footnote 2: Patients who were on short-term antiplatelets which included clopidogrel but are no longer on clopidogrel prior to stroke would fulfil for this inclusion criteria. In this context, short-term antiplatelets are defined as 21 days for minor stroke TIA and 3 months for large vessel disease. Exclusion Criteria: * Known diagnosis of dementia \[Refer to footnote 3\]. * Known diagnosis of a life limiting illness with life expectancy of less than 1 year. * Known cardioembolism or prothrombotic state necessitating the use of anticoagulation, or having a contraindication to clopidogrel. Footnote 3: "Known diagnosis of dementia" will be defined as clinical diagnosis of dementia prior to the index stroke event as indicated in the patient's medical records.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke transient ischemic attack

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ischemic stroke Transient ischemic attack

Contacts and locations

Locations

  • Singapore General Hospital

    Singapore, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.